MedTrace Logo

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

NCT00376103 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2009-09-18

No results posted yet for this study

Summary

The purpose of this study is to determine treatment related toxicity, tumor response, progression-free survival and quality of life of newly diagnosed Glioblastoma Multiforme (GBM) patients undergoing a combination of surgical resection, brachytherapy and external beam radiation with concomitant temozolomide, followed by adjuvant temozolomide.

Conditions

Interventions

DRUG

temozolomide

75 mg/m2/day

PROCEDURE

Brachytherapy

60 Gy to 1 cm

PROCEDURE

External Beam Radiation Therapy

60 Gy

Sponsors & Collaborators

  • Methodist Healthcare

    lead OTHER

Principal Investigators

  • Allen K Sills, MD · Methodist University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00376103 on ClinicalTrials.gov